Takeda Announces Results from First-of-Its-Kind Phase IIIb/IV Trial PROPEL -- a Randomized PK-Guided Prophylaxis Study Evaluating Higher Factor VIII Levels in Hemophilia...
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Feb 6, 2019--Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) ("Takeda"), the global biotechnology leader in rare disea…
